Despite the large amount of knowledge that connects Ang II and NF-κB signaling, the exact molecular mechanism as to how the activated Ang II receptor signals to NF-κB remains unclear. A previously undescribed signaling pathway has recently been shown to mediate Ang II-dependent activation of NF-κB. In this signaling pathway, three major proteins are involved: caspase recruitment domain (CARD) 10 (also known as CARMA3, for caspase recruitment domain-membrane-associated guanylate Abstract-Angiotensin (Ang) II is a potent mediator of both hypertension and cardiac damage; however, the mechanisms by which this occur remain unclear. B-cell lymphoma/leukemia 10 (Bcl10) is a member of the CBM signalosome, which links Ang II and nuclear factor-κB signaling. We hypothesized that Bcl10 is pivotal in the pathogenesis of Ang II-induced cardiac damage. Ang II infusion in mice lacking Bcl10 resulted in reduced cardiac fibrosis, less cellular infiltration, and improved arrhythmogenic electric remodeling, despite a similar degree of hypertension or cardiac hypertrophy. 
H ypertension promotes cardiomyocyte growth, cardiac hypertrophy, and arrhythmias. 1, 2 In several hypertension models, monocytes/macrophages and T lymphocytes infiltrate the perivascular region of the heart and initiate perivascular and interstitial extracellular matrix formation. 3 More recently, macrophage and T-cell subsets have been implicated in the pathogenesis of hypertension and cardiovascular remodeling. [4] [5] [6] Angiotensin (Ang) II-initiated inflammation is involved in these processes, [7] [8] [9] particularly in the heart. 10 Ang II activates the nuclear factor kappa light chain enhancer of activated B cells (NF-κB), a major transcription factor regulating various aspects of inflammatory responses. 11 We have shown previously that NF-κB is upregulated in Ang II-dependent target-organ damage 12 and that pharmacological NF-κB inhibition 12 or endothelial-specific NF-κB inhibition reduced targetorgan damage independent of blood pressure. kinase), B-cell lymphoma/leukemia 10 (Bcl10), and mucosaassociated lymphoid tissue lymphoma translocation protein 1. Together, these three proteins comprise the CBM signalosome. 14 Originally, Bcl10 was identified as a target of a chromosomal translocation in mucosa-associated lymphoid tissue lymphoma translocation protein 15 and was linked to normal lymphocyte function as a member of the CARMA1-containing CBM signalosome used by lymphocytes. 16 However, Bcl10 functions as part of a CARMA3-containing CBM signalosome outside of the immune system. Of particular relevance to cardiovascular biology, Bcl10-deficient ApoE −/− mice were protected from developing Ang II-dependent atherosclerosis and aortic aneurysms. 17 To date, no studies have investigated the role of the CBM signalosome in Ang II-mediated cardiac damage. In this study, we investigated the role of Bcl10, the bridging molecule of the CBM signalosome, and further aimed to discriminate its role in immune cells and in the heart in Ang II/hypertensioninduced cardiac damage, including cardiac fibrosis and electric remodeling.
Methods
Detailed description of methods is available in the online-only Data Supplement. Primers used for quantitative polymerase chain reaction are listed in Table S1 .
Results

CBM Signalosome Expression in Target Organs
We first confirmed the expression of the CBM signalosome components in Ang II responsive tissues in wildtype (WT) mice. Similarly to published data, 14 we found high expression of CARMA3, Bcl10, and mucosa-associated lymphoid tissue lymphoma translocation protein 1 in the heart, kidney, and liver, whereas CARMA1 was restricted to lymphoid organs, such as the spleen ( Figure S1 ). Infusion of Ang II in any of our study groups did not change the expression of the signalosome in the heart ( Figure S2 ).
Lacking Bcl10 Leads to Reduced NF-κB Activation in the Heart
Intraperitoneal injection of Ang II led to increased NF-κB activity in the heart of WT mice, whereas this increase was reduced in the heart of the Bcl10 knockout (KO) mice as measured by the electrophoretic mobility shift assay ( Figure S3A-S3C ).
Bcl10 Deficiency Is Protective Despite Hypertension
Both WT and Bcl10 KO mice were normotensive and showed no difference in blood pressure at baseline measured by radiotelemetry. Ang II infusion led to similarly high blood pressure in both WT and Bcl10 KO animals ( Figure 1A ). Accordingly, both groups of mice developed a similar degree of cardiac hypertrophy defined by echocardiography ( Figure 1B ; Table  S2 ), heart weight-to-body weight ratio ( Figure 1C ), heart weight-to-tibia length ratio ( Figure S4A ), and the hypertrophy markers brain natriuretic peptide ( Figure 1D ) and atrial natriuretic peptide ( Figure S4B ). Despite the high blood pressure, Ang II-treated Bcl10 KO mice showed less CD4+ and CD8+ T cell and macrophage infiltration ( Figure 1E ) and developed significantly less perivascular ( Figure 1F ) and interstitial ( Figure 1G ) cardiac fibrosis compared with Ang II-infused WT counterparts. Quantification confirmed the histological results ( Figure 1H and 1I). Next, we determined the expression levels of genes known to mediate cardiovascular remodeling, including fibrosis. Ang II infusion led to increased cardiac expression of transforming growth factor-β ( Figure S5A ), connective tissue growth factor ( Figure S5B ), and interleukin (IL)-6 ( Figure S6A ) in both WT and Bcl10 KO mice, whereby transforming growth factor-β was not but connective tissue growth factor and IL-6 were significantly reduced in mice lacking Bcl10. More interestingly, short-term (30 minutes) Ang II treatment led to an immediate elevation in IL-6 expression, but not in Bcl10 KO mice ( Figure S6B ). These data indicate that Ang II-mediated IL-6 expression by Bcl10 is controlled not only at transcriptional level but at the mRNA level too. It has recently been shown that IL-6 is destabilized by a novel ribonuclease named Regnase-1, which is partly under the control of the Bcl10. 18 Short-term Ang II infusion did not lead to Regnase-1 degradation in the heart, nor did treatment of mouse embryonic fibroblast cells (NIH3T3) overexpressing the type 1 angiotensin II receptor with Ang II (Figure S6C-S6D ). These data suggest that Bcl10-dependent expression of IL-6 in the heart may be regulated by other ribonuclease(s).
Arrhythmogenic Electric Remodeling Is Improved in the Absence of Bcl10
To investigate the pathophysiological relevance of reduced infiltration of immune cells and reduced fibrosis in Ang II-treated Bcl10 KO mice, we performed electrophysiological studies. Arrhythmias (Figure 2A ) during programmed electric stimulation could be induced in all Ang II-infused WT mice (5/5), but only in 25% of Ang II-treated Bcl10 KO mice (1/4; Figure S7A ). The amount of the inducible nonsustained ventricular arrhythmia protocols (as detailed in the online-only Data Supplement) was significantly higher in Ang II-infused WT (67%) compared with Bcl10 KO (8%) mice ( Figure 2B ). The ventricular effective refractory period was also assessed. Bcl10 KO mice treated with Ang II showed higher ventricular effective refractory period compared with Ang II-treated WT controls (37.3±3.8 versus 32.0±1.3 ms; Figure S7B ). Connexin-43 (Cx43), the major cardiac gap junction protein in intercalated disks, was redistributed toward the lateral borders of cardiomyocytes in Ang II-treated WT mice ( Figure 2C ). In contrast, Ang II-treated Bcl10 KO mice showed almost unaltered Cx43 protein localization with restriction to the intercalated discs similar to WT and Bcl10 KO control mice ( Figure S7C ). Furthermore, Ang II-treated Bcl10 KO mice displayed significantly less severe QRS interval prolongation compared with Ang II-infused WT controls (12.1±0.2 versus 13.7±0.3 ms; Figure S5D ); other electrocardiography parameters were similar.
Bcl10 in Bone Marrow and Heart Affects Inflammation and Fibrosis
To understand which cell types were pivotal in the amelioration of cardiac damage in the Ang II-infused Bcl10 KO mice, we performed bone marrow (BM) transplantation studies (as depicted on Figure 3A ; verification of successful BM transplantation is shown on Figure S8 ). All Ang II-treated transplanted groups developed a similar level of cardiac hypertrophy defined by echocardiography ( Figure 3B ; Table S3 ), heart weight-to-body weight ratio ( Figure 3C ), heart weight-to-tibia length ratio ( Figure S9A ), and hypertrophy markers brain natriuretic peptide ( Figure 3D ) and atrial natriuretic peptide ( Figure S9B ), confirming the results in complete Bcl10 KO with Ang II. Surprisingly, after Ang II treatment, both WT mice that received Bcl10 KO BM and Bcl10 KO mice that received WT BM showed less macrophage, CD4+, and CD8+ cell infiltration ( Figure 3E ), as well as less perivascular collagen I ( Figure 3F ) and reduced interstitial fibronectin deposition ( Figure 3G ) compared with control WT mice receiving WT BM. Quantification of collagen I staining ( Figure 3H ) and fibronectin ( Figure 3I ) was confirmatory.
Bcl10 Is Required for Cell Adhesion and Chemotaxis
To pursue the mechanisms as to how Bcl10 deficiency in the heart reduces immune cell infiltration, we next analyzed the expression vascular cell adhesion molecule-1, which is a target gene of NF-κB. Immunohistological analysis revealed that after Ang II treatment, Bcl10 KO mice transplanted with WT BM expressed significantly less vascular cell adhesion molecule-1, as measured by a lower number of affected vessels, as well as a lower magnitude of vascular cell adhesion molecule-1 expression in the respective endothelium ( Figure 4A ). These results were confirmed on the mRNA level ( Figure 4B ). Other target genes of NF-κB, which are important for cell adhesion and for chemotaxis, also had reduced expression in Bcl10 KO mice recipient of WT BM as compared with the two other groups (Figure S10A-S10C). To further test the hypothesis that Bcl10 mediates Ang II-dependent cell adhesion to endothelial cells, we performed an in vitro monocyte/endothelial adhesion assay. Endothelial cells transfected with control siRNA showed a >20-fold increase in monocyte attachment after Ang II treatment, whereas those transfected with Bcl10 siRNA showed only a 4-fold increase ( Figure 4C-4E) . 
Bcl10 Is Required for Monocyte/Macrophage Migration
Recently, Bcl10 was shown to play a role in F-actin polymerization within cells of the immune system, 19 a process required for cell motility. 20 To further understand as to why WT mice recipient of Bcl10 KO BM had reduced immune cell infiltration, despite high expression of adhesion molecules and chemokines ( Figure S10A -S10C, white bar), we performed an in vitro chemotaxis assay. Chemotaxis toward monocyte chemotactic protein-1 (MCP-1) was significantly higher in WT BM-derived macrophages compared with Bcl10 KO BM-derived macrophages ( Figure 5A and 5B). These 
Infiltration of BM-Derived (Myo)fibroblasts Are Reduced by Bcl10 Deficiency
The origin of cardiac fibroblasts which promote fibrosis is still not completely understood. 21 Recent data suggests that BM-derived cells could represent an important source of such cardiac fibroblasts. 22 We hypothesized that the cardiac recruitment of these BM-derived fibroblasts could be altered by the lack of Bcl10. To this end, green fluorescent protein (GFP+) WT BM was transplanted into irradiated WT and Bcl10 KO recipients, and the mice were infused with Ang II as previously described. Ang II infusion led to a rise in the number of fibroblast-specific protein 1 positive (FSP1+) cells in the heart of WT and Bcl10 KO mice; however, Bcl10 KO heart samples had significantly less number of FSP+ cells ( Figure 6A Figure 6C ). Furthermore, FSP1 costaining with myofibroblast marker α-smooth muscle actin indicates that these fibroblasts are able to produce extracellular matrix ( Figure S11 ).
Discussion
The present study highlights the importance of Bcl10, a major component of the recently described nonimmune cell CBM signalosome, in Ang II-mediated cardiac damage. The current results clearly show that deletion of Bcl10 is enough to circumvent severe fibrosis, inflammation, and susceptibility to ventricular arrhythmias, despite a similar elevation in blood pressure and cardiac hypertrophy. Moreover, this study shows that Bcl10 plays an important role both in BM-derived cells and in the heart, in the development of Ang II-mediated cardiac damage, albeit in different ways. Several studies have provided evidence for an important role of NF-κB in the development of cardiac end-organ damage in various hypertension models, including Ang II. 12, 23, 24 However, the exact molecular mechanism as to how Ang II activates NF-κB is not completely understood. Recently, a complex of proteins, including CARMA3, Bcl10, and mucosa-associated lymphoid tissue lymphoma translocation protein 1, was shown to be involved in the transmission of the signal from the type I angiotensin II receptor to NF-κB. 14 We hypothesized that Bcl10 deficiency would play an important role in Ang IIinduced cardiac damage and electric remodeling. In our study, Ang II-treated Bcl10 KO mice developed similar elevations in blood pressure and cardiac hypertrophy compared with WT mice. However, cardiac fibrosis and inflammatory cell infiltration was reduced in the infused Bcl10 KO mice. Fibrosis and inflammation are factors known to play an important role in electric remodeling of the heart, which increases susceptibility to arrhythmias. 25 Thus, patients with hypertension-induced cardiac damage are prone to arrhythmias, which contributes to the increased cardiovascular mortality in these patients. 26 Our programmed electric stimulations revealed that Ang II-treated Bcl10 KO mice were less vulnerable for the inducibility of arrhythmias compared with their Ang II-treated WT controls. This improvement was accompanied by higher ventricular effective refractory period, which also decreases the likelihood of ventricular arrhythmias. 27 Ang II-induced cardiac hypertrophy was also associated with QRS prolongation in WT and Bcl10 KO mice. The duration of QRS complex in untreated animals of the same age under the same conditions lies between 10 and 11 ms. Bcl10 KO mice displayed significantly less severe QRS interval prolongation. QRS prolongation indicates slowing of ventricular conduction and is often associated with hypertrophy, structural, and electric remodeling, including fibrosis, as well as Cx43 delocalization, and has been considered as a predictor of mortality in congestive heart failure patients. 28, 29 Consistent with the less severe QRS interval prolongation, we found that Bcl10 KO mice showed normal Cx43 localization at the intercalated disc regions after 2 weeks of Ang II infusion, whereas in Ang II-treated WT mice, Cx43 was partially redistributed toward the lateral borders of cardiomyocytes.
To determine whether the ameliorated phenotype of Bcl10 KO mice was caused by resident cardiac cells or alternatively by the infiltration of noncardiac cells, we performed a series of BM transplantation studies. Although cardiac hypertrophy was not altered in any of the transplant groups, Ang II-induced cardiac fibrosis and immune cell infiltration was reduced both in WT mice recipient of Bcl10 KO BM and in Bcl10 KO mice recipient of WT BM. These results suggest that Bcl10 has a multifactorial role in both BM and cardiac compartments.
First, our findings with Bcl10 KO mice recipient of WT BM suggested that the CBM signalosome is playing an important role in resident cells of the heart. Accordingly, we found evidence that Bcl10 is required for Ang II-dependent induction of the adhesion molecule vascular cell adhesion molecule-1 within endothelial cells and for cardiac expression of the chemokines, such as MCP-1 and chemokine (C-C motif) ligand 5, which play an essential role in recruiting immune cells to the heart. We also provide the first evidence that Ang IIdependent adhesion of monocytes to endothelial cells requires an intact CBM signalosome. These data are in line with the findings that Bcl10 KO mice are protected from developing Ang II-dependent atherosclerotic lesions and aortic aneurysms. 17 Together, these data suggest that Bcl10 specifically in endothelial cells-through coordination of adhesion molecules and chemokine expression-regulates susceptibility to fibrosis. Second, our findings with WT mice, which were recipients of Bcl10 KO BM, suggested that the CBM signalosome plays an equally important role in the BM, in regards to the induction of cardiac damage. We found that Bcl10 KO monocyte/macrophage migrate less toward chemotactic stimuli like MCP-1 in vitro and in vivo. One putative mechanism to explain the role of Bcl10 in the BM stems from the recent finding that Bcl10 controls T-cell receptor and Fcγ receptor-induced F-actin polymerization in monocytes/macrophages and in T cells. 19 F-actin rearrangement is also a prerequisite of transendothelial migration of immune cells. 20 Although the reduced presence of immune cells could explain the reduction in cardiac fibrosis in Bcl10 KO mice, we have also considered other mechanisms. BM-derived cells could also represent an important source for fibroblasts in pathological fibrosis. This concept is supported by previous work, wherein BM-derived cells were shown to contribute to FSP1+ fibroblasts in an aortic banding model. 30 In nonbanded hearts, the number of FSP1+ cells was found to be low. 30 Similarly, we found few FSP1+ cells in untreated mice, but Ang II infusion led to a significant rise in the number of FSP1+ cells in the heart, which was found to be lower in Bcl10 KO hearts. By transplanting WT and Bcl10 KO mice with GFP+ WT BM, we were able to demonstrate that a substantial number (70%±4% in the case of transplanted WT mice and 42%±7% in the case of the Bcl10 KO mice) of the cardiac FSP1+ cells were also GFP+ and therefore BM-derived. Furthermore, these cells expressed the myofibroblast marker α-smooth muscle actin and were observed to be localized to the site of fibrotic areas, which supports their involvement in the development of fibrosis. This finding indicates that there are substantial numbers of noncardiac fibroblasts that may also contribute to cardiac fibrosis after Ang II infusion. Importantly, Bcl10 KO mice recipient of GFP+ WT BM showed a >50% reduction in GFP/ FSP1 double positive fibroblasts as compared with WT controls. We think that, in our experimental setting, the lower number of GFP+/FSP1+ cells in the hearts of Bcl10 KO mice is because of the lower expression of chemokines, such as MCP-1 because these were shown to regulate the mobilization and incorporation of BM-derived fibroblasts into the tissue. 22 Our data provided the first evidence that Bcl10, a protein which plays a major role in the assembly of NF-κB activator CBM signalosome, plays a substantial role in Ang II-induced cardiac fibrosis, cardiac inflammation, and electric remodeling. The lack of Bcl10 in both BM-derived cells and cardiac compartments led to a reduced infiltration of immune cells and BM-derived FSP1+ (myo)fibroblasts into the heart, which both contribute to the reduced cardiac fibrosis and enhanced electric remodeling. These findings implicate the CBM signalosome as a target for pharmaceutical development in the management of cardiac fibrosis and arrhythmias.
Perspectives
High blood pressure is a major cause of cardiovascular morbidity and mortality. Ang II is one of the major mediators of high blood pressure-caused cardiovascular damage. Nonetheless, the molecular mechanism of action is still not completely understood. Recently, a previously undescribed protein complex has been shown to mediate the Ang II-dependent activation of NF-κB; a transcription factor that has been implicated in Ang II-mediated cardiovascular damage. Bcl10 serves as a bridging molecule in the assembly of this complex. Here we show that Bcl10 both in cardiac and in immune cells plays a substantial role in Ang II-induced cardiac fibrosis, cardiac inflammation, and electric remodeling by regulating the migration of immune cells, ultimately leading to arrhythmogenic electric remodeling. These and previous findings strongly suggest that inhibition of this protein complex ameliorates Ang II-mediated NF-κB activation and cardiovascular damage and, therefore, can serve as a new target for pharmacological intervention.
What Is New?
• This study shows that B-cell lymphoma/leukemia 10, a bridging molecule of a recently discovered complex for NF-κB activation, mediates angiotensin II-induced cardiac damage and arrhythmogenic electric remodeling.
What Is Relevant?
• B-cell lymphoma/leukemia 10 plays a pivotal in immune and other bone marrow-derived cells, as well as in cardiac cells, by regulating the migration of immune cells, leading to cardiac inflammation, cardiac fibrosis, and arrhythmias.
Summary
Our findings, together with previous findings on angiotensin IImediated atherosclerosis, show that B-cell lymphoma/leukemia 10 is a powerful regulator of angiotensin II-mediated cardiovascular damage and, thus, is a promising new target for pharmacological intervention. 
Novelty and Significance
Supplementary Materials and Methods
Animals and study design First, to confirm that Ang II activates NF-B less in the hearts of the Bcl10 KO mice 1 , 3 mg/kg of Ang II was injected intraperitoneally into Bcl10 KO and C57BL/6 (wildtype; WT) littermates mice and the heart was harvested after 30 minutes for further analysis. After that Bcl10 KO and WT mice aged between 16-18 weeks were uni-nephrectomized and were left to recover for 1 week. To induce hypertension, we infused Ang II (1.44 mg/kg/d by subcutaneous mini-osmotic pumps) for 14 days. During the experiments, all mice received 1% NaCl (ad libitum) in the drinking water. Mean arterial blood pressure (MAP) was measured by radiotelemetry in a subgroup of the animals (n=4/group). Echocardiography was performed at day 12 after Ang II infusion and in vivo electrical stimulations in a subgroup of the animals (n=4 in Bcl10 and n=5 in WT group) at day 14. After two weeks, animals were sacrificed and blood and organs were collected. To distinguish the role of Bcl10 in circulating immune cells versus cardiac cells and to address the role of bone marrow-derived fibroblasts, we performed BM transplantation studies with 10-12 weeks old mice. After lethal total-body irradiation (9 Gy), BM from WT C57BL/6 or from green fluorescence protein transgenic WT C57BL/6 (GFP+ WT) mice was transplanted into WT (WT BM n=6, GFP+ WT BM n=4) or into Bcl10 KO (WT n=7 and GFP+ WT n=4) recipients as well as BM from Bcl10 KO into WT (n=7) recipients. Mice were kept under sterile conditions and were treated with antibiotics (Borgal, Intervet) for 6 weeks (to ensure full restoration of BM and peripheral immune cell numbers) followed by the above-described (UNX+Ang II+1% NaCl) protocol. The Berlin Animal Review Board approved all protocols that were conducted to American Physiological Society standards.
Cytoplasmic and nuclear extract preparation
Extracts preparation and EMSA was performed as described previously. 2 Briefly, organ pieces were homogenized using a tissue homogenizer (Precellys, Bertin Technologies) and centrifuged after. ) and were kept on ice for 5 minutes, followed by the addition of NP40 (0.1% final concentration). Lysates were vortexed briefly and pelleted. The resulting supernatant was referred to as the cytoplasmic fraction and stored at -80°C. For the preparation of nuclear extracts, the pellet was resuspended with the hypertonic, high-salt buffer C (HEPES 20 mM, pH 7.5, NaCl 0.4 M, EDTA 1 mM, EGTA 1 mM, glycerol 20%) together with the protease inhibitor cocktail for 30 minutes. After centrifugation (10 minutes at 14 000g, 4°C), the supernatant was collected and referred to as the nuclear fraction. Protein measurements were done using the Bio-Rad assay (Bio-Rad, Munich, Germany).
Electrophoretic mobility shift assay (EMSA)
For the electrophoretic mobility shift assay (EMSA), nuclear extracts (3 μg protein) were incubated with 25 000 cpm of a 22-bp oligonucleotide containing the NF-B consensus sequence that had been labeled with [-32] adenosine triphosphate (ATP) T4 polynucleotide kinase. Incubations were performed for 30 minutes at room temperature in the presence of polydeiodinase/deoxycytidine (poly/dI-dC) and 20 mM HEPES, containing 60 mM KCl, 4% Ficoll, 5 mM DTT, and 0.5 μg/μL nuclease-free bovine serum albumin (BSA). Probes were subjected to electrophoresis on native 5% polyacrylamide gels and autoradiographed. The oligonucleotides for H 2 K were forward primer: 5'-GATCCAGGGCTGGGGATTCCCCATCTCCACAGG-3', reverse primer: 5'-GATCCCTGTGGAGATGGGGAATCCCCAGCCCTG-3'. Specificity of the bands was assessed by competition with a cold probe and supershift experiments. A 10-fold excess of unlabeled NF-B probe and 5 specific antibodies against the family of the different members of the NF-B family were added to nuclear extracts before incubation with labeled NF-B oligonucleotide probe.
Cardiac hypertrophy and echocardiography
Cardiac hypertrophy was assessed by calculating the heart weight/body weight, heart weight/tibia length ratio and by means of echocardiography in a part of the study animals. A detailed protocol has been published elsewhere. 3 Briefly, anesthetized mice were analyzed with a 30-MHz transducer (RMV 707b, VisualSonics). Two-dimensionally targeted M-mode echocardiografic images were recorded from the parasternal short-axis view at the level of the papillary muscles as published. Intraventricular septal (IVS) and left ventricular posterior wall thickness (LVPW) were estimated at end diastole. Total left ventricular wall thickness was calculated by adding LVPW and IVS. An experienced reader blinded to treatment performed all measurements.
Histology and immunohistochemistry
Immunohistochemistry was performed on 5-µm ice-cold acetone-fixed cryosections of hearts using the following primary antibodies: anti-CD4, anti-CD8 (all BD Pharmingen, San Diego, CA, USA), anti-F4/80 (AbD Serotec, Oxford, UK), anti-fibronectin (Abcam, Cambridge, UK), anti-type I collagen (Southern Biotech, Birmingham, AL, USA), anti-connexin-43 (Sigma-Aldrich Chemie GmbH, Munich, Germany), anti-N-cadherin (Invitrogen, Paisley, UK), anti-VCAM-1 (AbD Serotec, Oxford, UK), anti-GFP, anti-FSP1 and anti-SMA (all Abcam, Cambridge, UK). For indirect immunofluorescence, nonspecific binding sites were blocked with 10% normal donkey serum (Jackson ImmunoResearch, West Grove, USA) for 30 min. Then sections were incubated with the primary antibody for 1 h at room temperature or overnight at 4°C. All incubations were performed in a humid chamber. For fluorescence visualization of bound primary antibodies, sections were further incubated with Cy3-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, USA) for 1 h in a humid chamber at room temperature. For fluorescence visualization of N-cadherin biotin conjugated secondary antibody and streptavidin (Alexa Fluor 568) and in case of Cx43 secondary antibody conjugated with Alexa Fluor 488 (all Invitrogen, Paisley, UK) was used and was incubated as mentioned before. Specimens were analyzed using a Zeiss Axioplan-2 imaging microscope with the computer program AxioVision 4.8 (Zeiss, Jena, Germany). The investigator had no knowledge of the treatment group assignment. For semi-quantitative analyses of infiltrating cells, CD4+, CD8+ or F4/80+ cells were counted in whole heart sections (n=4-6 per group). Fibronectin and collagen I deposition was quantitatively measured using the AxioVision 4.8 (Zeiss, Jena, Germany) software. Data are expressed as mean±SEM of whole heart section.
In vivo programmed electrical stimulation and electrocardiography (ECG)
Programmed electrical stimulation and ECG was performed in a group of the study animals (Bcl10 KO n=4, WT n=5) as described earlier. 4 Isoflurane anesthetized mice underwent surgical preparation of the right jugular vein and a 2 French octapolar electrophysiology catheter (CIB'ER mouse catheter from NuMed) was placed in the right heart, including atrium and ventricle. Programmed stimulation was performed by using a standardized protocol that included trains of 10 basal stimuli followed by up to 3 extra stimuli, delivered with a coupling interval decreasing in steps of 5 ms until ventricular or atrial refractory was reached. The stimulation procedures were repeated at three different basal cycle lengths (100, 90 and 80 ms). "Reproducible inducible protocols" was calculated as the percentage of effective (positive) out of total protocols applied (100, 90 and 80 ms). Accordingly, the arrhythmia inducibility of individual animals could take a value of 0, 33, 66 or 100%. For statistical evaluation, the data obtained for the individual animals in a given group were averaged and are given as mean±SEM. Occurrence and duration of inducible arrhythmias were documented. Only stimulation protocols with reproducible arrhythmias longer than five consecutive beats in ventricle were considered positive. A standard limb lead surface ECG was performed under slight isoflurane anesthesia by using skin electrodes. Calculation of standard ECG time-interval parameters were performed by two independent operators based on averaged ECG lead II waveforms. Correction for heart rate and definition of time points was performed as describe before.
RNA isolation and qRT-PCR
Total RNA was isolated from snap-frozen tissues using the RNeasy RNA isolation kit (Qiagen). RNA concentration and quality was measured by NanoDrop-1000 spectrophotometer (PeqLab). Two micrograms of RNA were used for cDNA transcription (Applied Biosystems). Quantitative analysis of target mRNA expression was performed with real-time (RT)-PCR using the relative standard curve method. TaqMan and SYBR green analysis was conducted using an Applied Biosystems 7500 Sequence Detector (Applied Biosystems). The expression level of the target genes was normalized by hypoxanthineguanine phosphoribosyltransferase (HPRT) or by 18s (only in case of Supplementary material online, Figure S1 ). Biotez synthesized the primers and the sequences are provided in the in online supplement (Supplementary material online, Table S1 ). Primer efficiency was calculated from the slopes of the standard curves according to the following formulas: E = (10 (-1/slope) -1)100 and was between 89.71% and 105.17%.
RNA interference
Bcl10 was targeted with the use of a siRNA pool from Dharmacon (ON-TARGETplus SMARTpool). In brief, the cells were transfected with gene-specific siRNA or nontargeting siRNA at a concentration of 10 nM using Lipofectamine RNA iMAX reagent (Invitrogen), according to the manufacturer's instructions. The cells were allowed to recover for 48-72 h to achieve maximal knockdown.
Cell Culture and transfection
A mouse fibroblast cell line, NIH3T3 cells, at 70 to 80% confluence in DMEM supplemented with 10% FBS, penicillin (100 U/ml), streptomycin (100 g/ml) were transfected with the human type 1 angiotensin II receptor (AT1R) cDNA using the FuGENE HD Transfection Reagent (Roche) according to the manufacturer's protocol. Six hours after transfection the cells were serum starved overnight and the next day they were stimulated with 10-7 M Ang II or LPS (100ng/ml) for the indicated time.
Western blot
After lysing cells and tissues with radioimmune precipitation assay buffer containing protease and phosphatase inhibitors, immunoblotting was performed as described.
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Monocyte/endothelial adhesion SVEC4-10 cells (ATCC) were grown in DMEM with 10% FBS. Cells were transfected with control or Bcl10-specific siRNAs as described above and allowed to grow to confluence. After an overnight serum starvation, the cells were then treated with or without 2µM Ang II for 6 hrs. WEHI-274.1 mouse monocytes (ATCC) were then added to the culture medium (6 x10 5 cells/well for a 6-well plate). Monocytes were allowed to attach for 10 min, followed by vigorous washing, and the number of monocytes remaining attached to the endothelial monolayer were counted using an inverted bright field microscope. For each well, the total number of attached monocytes was tallied in seven random 20x fields.
Bone marrow-derived macrophages
Bone marrow was flushed out from femurs and passed through a 70 μm cell strainer to remove debris. Red blood cells were removed by lysis. Bone-marrow derived monocytes were then cultured in Teflon bags in RPMI-1640 with L-glutamine, 10% FBS, 1% penicillinstreptomycin and L929-conditioned medium (M-CSF) for 7 days to generate macrophages.
In vitro macrophage chemotaxis assay BM-derived macrophages (0.2×10 6 cells/well) were placed in the upper wells of Boyden chamber (24-well with 8.0µm pore polycarbonate membrane insert (Transwell, Corning Costar)). The bottom chamber contained MCP-1 (30 ng/ml). Following incubation at 37°C for 1, 2 and 4 hours, the upper wells were removed and migrated cells in the lower chamber were counted manually under the microscope (×20), following fixation with formaldehyde (4% in PBS) and staining with hematoxylin-eosin.
Estimation of monocyte/macrophage recruitment to the peritoneal cavity
We used the method of Han et al described earlier. 6 Briefly, recombinant MCP-1 (500 ng/mouse) or PBS was injected into the peritoneal cavity of WT and Bcl10 KO. After 6 h mice were euthanized and peritoneal cavities of each mouse were lavaged with 10 ml of PBS containing equal amount of PE-conjugated microbeads (Becton Dickinson). Cells were centrifuged, stained with PE-conjugated monocyte/macrophage marker CD11b and the number was counted by flow cytometry and expressed per 10 3 PE-conjugated microbeads.
Flow cytometry
For the monocyte/macrophage recruitment assay up to 3.5 x 10 6 peritoneal cells were suspended in PBS+0.1% FCS and incubated with an optimal concentration of PE-CD11b antibody (clone: M1/70 (#557397)). The cells were analyzed on FACSCanto II flow cytometer (all Becton Dickinson). For further analyses either FACSDiva or FlowJo (TreeStar Inc.) software was used.
Statistical analysis
Statistical analysis was performed using GraphPad 5.04 (GraphPad Software Inc.) and SPSS 13.0 (SPSS Inc.) software. Normality of the data was tested by Kolmogorov-Smirnov test. Data of normal distribution were analyzed by one-way ANOVA using Tukey's post-hoc test in case of more than 2 groups. Mann-Whitney's U-test (data with non-normal distribution) or unpaired t-test (data with normal distribution) was in case of 2 groups as stated in figure legends. Data are presented as mean±SEM. P values <0.05 were considered as statistically significant. 
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Supplemental Figure 4 A B Figure S4 . Cardiac hypertrophy in angiotensin (Ang) II-infused mice. (A) Cardiac hypertrophy assessed by calculating the ratio of cardiac weight to tibia length and (B) by measuring the expression of atrial natriuretic peptide (ANP) was similar before Ang II treatment and raised to similar level in both groups. *P<0.05 versus WT and Bcl10 KO, oneway ANOVA using Tukey's post-hoc test, n=4 in untreated groups, n=5 in Bcl10±Ang II and n=9 in WT±Ang II groups.
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Supplemental Figure 5 A B Figure S5 . Cardiac expression of (A) transforming growth factor beta (TGF-β) and (B) connective tissue growth factor (CTGF) after 2 weeks of saline or Ang II treatment (A) in the heart of wild-type (WT) and Bcl10 knockout (KO) mice. *P<0.05 versus WT and Bcl10 KO, #P<0.05 versus WT, &P<0.05 versus WT+Ang II, one-way ANOVA using Tukey's post-hoc test, n=4 in untreated groups, n=5 in Bcl10±Ang II and n=9 in WT±Ang II groups. 
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Supplemental Figure 9 A B Figure S9 . Expression of cardiac hypertrophy markers in bone marrow (BM)-transplanted mice. Cardiac hypertrophy assessed by (A) calculating the ratio of cardiac weight to tibia length and by (B) atrial natriuretic peptide (ANP) showed no differences between the transplanted group. N=9 in WT BM→WT, n=7 in Bcl10 KO BM→WT and n=4 WT BM→Bcl10 KO groups.
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Supplemental Figure 10 
